COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

摘要

During the COVID-19 pandemic, patients with neuromuscular disorders, especially patients with autoimmune myasthenia gravis, might be at greater risk of worse outcomes than otherwise healthy people because of an immunocompromised state related to immunotherapy and possible respiratory and bulbar muscular weakness. However, cessation of immunotherapy in neuroinflammatory disorders has severe risks as well.1 Moreover, infections are a well recognised trigger of symptom exacerbation in patients with myasthenia gravis, and some drugs used in therapeutic trials early in the pandemic, including hydroxychloroquine2 and azithromycin,3 can provoke symptom exacerbations.